SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ®-HD2 study of INGREZZA ® (valbenazine) ...

Huntington’s disease, also known as Huntington’s chorea and formerly called “Saint Vitus’ dance,” is a rare, hereditary disorder of the central nervous system. It is characterized by jerky movements ...

This type of medication can help manage the uncontrolled movements that can occur with Huntington’s disease. Huntington’s disease is a neurodegenerative disorder that causes a progressive breakdown of ...

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with ...

SAN DIEGO -- Treatment with investigational pridopidine seemed to offer benefits for certain patients with Huntington's disease, according to subgroup analysis of the PROOF-HD trial. Those ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...